Oxysterols and methods of use thereof
US-2018201643-A1 · Jul 19, 2018 · US
Neuroactive steroids and methods of use thereof
US11905309B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11905309-B2 |
| Application number | US-202117381829-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 21, 2021 |
| Priority date | Mar 13, 2013 |
| Publication date | Feb 20, 2024 |
| Grant date | Feb 20, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of: and pharmaceutically acceptable salts thereof. 2. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier. 3. The compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 4. The pharmaceutically acceptable salt of a compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 5. A pharmaceutical composition comprising the compound according to claim 3 and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 4 and a pharmaceutically acceptable carrier. 7. The compound according to claim 1 wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 8. The pharmaceutically acceptable salt of a compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 9. A pharmaceutical composition comprising the compound according to claim 7 and a pharmaceutically acceptable carrier. 10. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 8 and a pharmaceutically acceptable carrier. 11. The compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 12. The pharmaceutically acceptable salt of a compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 13. A pharmaceutical composition comprising the compound according to claim 11 and a pharmaceutically acceptable carrier. 14. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 12 and a pharmaceutically acceptable carrier. 15. The compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 16. The pharmaceutically acceptable salt of a compound according to claim 1 , wherein the compound has the structure: and wherein the absolute stereochemistry is as shown. 17. A pharmaceutical composition comprising the compound according to claim 15 and a pharmaceutically acceptable carrier. 18. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 16 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol · CPC title
- C07J9/005Primary
containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton · CPC title
- C07J9/00Primary
Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane · CPC title
with double bond in position 16 (17) · CPC title
with double bond in position 17 (20) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11905309B2 cover?
- 3beta, 17beta disubstituted steroidal compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, are provided for the prevention and treatment of a variety of CNS-related conditions.
- Who is the assignee on this patent?
- Sage Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07J9/005. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).